Your browser doesn't support javascript.
loading
Statistical and practical considerations in planning and conduct of dose-optimization trials.
Yuan, Ying; Zhou, Heng; Liu, Suyu.
Afiliação
  • Yuan Y; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Zhou H; Biostatistics and Research Decision Sciences, Merck and Co., Inc, Rahway, NJ, USA.
  • Liu S; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Clin Trials ; 21(3): 273-286, 2024 Jun.
Article em En | MEDLINE | ID: mdl-38243399
ABSTRACT
The U.S. Food and Drug Administration launched Project Optimus with the aim of shifting the paradigm of dose-finding and selection toward identifying the optimal biological dose that offers the best balance between benefit and risk, rather than the maximum tolerated dose. However, achieving dose optimization is a challenging task that involves a variety of factors and is considerably more complicated than identifying the maximum tolerated dose, both in terms of design and implementation. This article provides a comprehensive review of various design strategies for dose-optimization trials, including phase 1/2 and 2/3 designs, and highlights their respective advantages and disadvantages. In addition, practical considerations for selecting an appropriate design and planning and executing the trial are discussed. The article also presents freely available software tools that can be utilized for designing and implementing dose-optimization trials. The approaches and their implementation are illustrated through real-world examples.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Projetos de Pesquisa / Dose Máxima Tolerável Tipo de estudo: Prognostic_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Projetos de Pesquisa / Dose Máxima Tolerável Tipo de estudo: Prognostic_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Ano de publicação: 2024 Tipo de documento: Article